Maynard Um
-
-
-
-
-
-
-
Tevogen signs letter of intent to evaluate CRO acquisition
-
-
-
-
-
-
-
Tevogen Bio estimates pipeline drug value at $250 million for cancer treatment
-
-
-
-
-
-
-
Tevogen Bio reports 74% insider ownership of outstanding shares
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Shares 2024 Financing Activity
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Reports Nasdaq Listing Compliance, CEO Reaffirms Commitment in Bridging the Information Gap About the Company
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Extends Pipeline Prioritizing Oncology and Long COVID
-
401,060 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

